Intramural hematoma (IMH) is a newly defined disease entity and the optimal management is still controversial as the disease shows varied clinical course. We present a case of type B IMH, initially presenting with paraplegia progressing to segmental aortic dissection (SAD) which the formed dissection displayed as a segmental distribution pattern. To our knowledge, it may become a new progression pattern of IMH progression. The SAD was successfully treated with both thoracic and abdominal endovascular aortic repair (TEVAR plus EVAR). In 1-year follow-up, the patient recovered almost completely with moderately neurological deficit and the blood pressure is in control.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0031-1298067 | DOI Listing |
J Neuropathol Exp Neurol
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
In modern war theaters, exposures to blast overpressures are one of the most common causes of brain injury. These pervasive events result in acute and chronic cerebrovascular degenerative processes. Using a rat model of blast-induced mild traumatic brain injury, we identified intramural periarterial hematomas as early primary acute lesions induced by blast exposures.
View Article and Find Full Text PDFJ Anal Toxicol
January 2025
Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, PA.
Identification of N,N-dimethylpentylone (DMP) in counterfeit "Ecstasy" and "Molly" tablets poses risk to public health due to its adverse effects. Little information is available regarding the pharmacological activity or relevant blood or tissue concentrations of DMP, and even less is known about other structurally related beta-keto methylenedioxyamphetamine analogues on recreational drug markets, such as N-propyl butylone. Here, a novel toxicological assay utilizing liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) was developed and validated for the quantitation of DMP and five related synthetic cathinones (eutylone, pentylone, N-ethyl pentylone (NEP), N-propyl butylone, and N-cyclohexyl butylone), with chromatographic resolution from isomeric variants and quantitation performed by standard addition.
View Article and Find Full Text PDFBr J Haematol
January 2025
Oncogenesis and Development Section, Translational and Functional Genomics Branch (TFGB), National Human Genome Research Institute (NHGRI), Bethesda, Maryland, USA.
Lancet Public Health
January 2025
Background: Educational disparities in life expectancy in the USA have been documented nationally but have not been comprehensively explored at the county level. Such geographical granularity is necessary for determining how these disparities vary across the country, thus highlighting the populations that could benefit most from increased access to educational support. We aim to estimate life expectancy at age 25 years for US counties from 2000 to 2019 for four educational attainment populations: less than high school, high-school graduate (including certificate of high school equivalency or other alternative credentials), some college (including associate degrees and incomplete college), and college graduate (including graduate and professional degrees).
View Article and Find Full Text PDFAm J Cardiol
January 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Background: The benefit of mechanical circulatory support (MCS) with Impella (Abiomed, Inc, Danvers, MA) for patients undergoing non-emergent, high-risk percutaneous coronary intervention (HR-PCI) is unclear and currently the subject of a large randomized clinical trial (RCT), PROTECT IV. While contemporary registry data from PROTECT III demonstrated improvement of outcomes with Impella when compared with historical data (PROTECT II), there is lack of direct comparison to the HR-PCI cohort that did not receive Impella support.
Methods: We retrospectively identified patients from our institution meeting PROTECT III inclusion criteria (left ventricular ejection fraction [LVEF] <35% with unprotected left main or last remaining vessel or LVEF <30% undergoing multivessel PCI), and compared this group (NonIMP) to the published outcomes data from the PROTECT III registry (IMP).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!